Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia

Blood

Volumn 97, Issue 11, 2001, Pages 3665-3667

  Mesa, Ruben A ^a,b   Li, Chin Yang ^a,b   Schroeder, Georgene ^a,b   Tefferi, Ayalew ^a,b  

^a Division of Hematology and Internal Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW; CYTOGENETICS; CYTOPENIA; EXTRAMEDULLARY HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MICROSCOPY; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; SPLEEN; SPLEEN INFARCTION; SPLENECTOMY; SURVIVAL; THROMBOCYTE COUNT;

EID: 0035383813     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3665     Document Type: Article

References (16)

1. Dameshek W. Some speculations on the myeloproliferative syndromes [editorial]. Blood. 1951;6: 372-375.
2. Zhang B, Lewis SM. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol. 1989;43:63-66.
3. Wilkins BS, Green A, Wild AE, Jones DB. Extramedullary haematopoiesis in fetal and adult human spleen: a quantitative immunohistological study. Histopathology. 1994;24:241-247.
4. Calhoun DA, Li Y, Braylan RC, Christensen RD. Assessment of the contribution of the spleen to granulocytopoiesis and erythropoiesis of the midgestation human fetus. Early Hum Dev. 1996;46: 217-227.
5. Thiele J, Klein H, Falk S, Bertsch HP, Fischer R, Stutte HJ. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis: an immunohistological and morphometric study with comparison of corresponding bone marrow features. Acta Haematol. 1992;87:176-180.
6. Douay L, Laporte JP, Lefrancois G, et al. Blood and spleen haematopoiesis in patients with myelofibrosis. Leuk Res. 1987;11:725-730.
7. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
8. Porcu P, Neiman RS, Orazi A. Splenectomy in agnogenic myeloid metaplasia [letter]. Blood. 1999;93:2132-2134.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Wolf BC, Banks PM, Mann RB, Neiman RS. Splenic hematopoiesis in polycythemia vera: a morphologic and immunohistologic study. Am J Clin Pathol. 1988;89:69-75.
11. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
12. Wolf BC, Neiman RS. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. Hematol Pathol. 1987;1:77-80.
13. Litam PP, Friedman HD, Loughran TP Jr. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med. 1993; 118:954-955.
14. O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer. 1989;63:1539-1543.
15. de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W. The kinetics of murine hematopoietic stem cells in vivo in response to prolonged increased mature blood cell production induced by granulocyte colony-stimulating factor. Blood. 1995;86: 2986-2992.
16. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol. 1984;57:495-503.